ACRP discusses the enduring significance of leveraging real-world evidence (RWE) in clinical trials, as emphasized by former FDA Commissioner Scott Gottlieb. Gottlieb asserts that RWE is here to stay, thanks to substantial resources allocated by Congress in the 2019 budget, enabling the FDA to utilize RWE for evaluating drug and device safety.
Read More
Read More